Ligand Pharmaceuticals (LGND)
(Delayed Data from NSDQ)
$86.88 USD
+2.51 (2.97%)
Updated Jul 8, 2024 04:00 PM ET
After-Market: $86.88 0.00 (0.00%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
LGND 86.88 +2.51(2.97%)
Will LGND be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for LGND based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for LGND
Bristol Myers' (BMY) Krazati Gets FDA Nod for Colorectal Cancer
Gilead (GILD) Up as Twice-Yearly HIV Shot Prevents Infection
LGND: What are Zacks experts saying now?
Zacks Private Portfolio Services
Roche (RHHBY), Ascidian Team Up for RNA Exon Editing Therapeutics
Terns (TERN) Gains 13.6% YTD: Will the Momentum Continue?
Roche (RHHBY) Reports Upbeat Data on Columvi From STARGLO Study
Other News for LGND
Ligand Pharma’s Growth Outlook Bolstered by COPD Drug Approval and Strategic Oncology Royalty Deal
Craig-Hallum Sticks to Their Buy Rating for Ligand Pharma (LGND)
Ligand earns $5.8M milestone payment following FDA approval of Ohtuvayre
Ligand Collaborator Merck Receives FDA Approval for CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Adults
Ligand collaborator Merck receives FDA approval for CAPVAXIVE